Blend of PARP Inhibitors Shows Promising Activity against Small Cell Lung Cancer

Release Date: 20-Sep-2019

A combination of olaparib and temozolomide appeared safe and active in patient with relapsed small cell lung cancer (SLSC). Both the drugs belong to the class of Poly (ADP-ribose) polymerase (PARP) inhibitor. This result comes from the single-arm phase 1/2 trial. The findings were published online August 15, 2019, in Cancer Discovery.


The trial included a phase 1 dose-enhancement portion followed by a dose-expansion protocol during phase 2. The clinical trial consist of about a total of 50 patients with previously treated SCLC were enrolled across the 2 phases of the trial. Patients received a median of 2 lines of prior therapy (range, 1andndash;7), and the majority of patients (72%) had platinum-sensitive disease.


Four dose levels were evaluated during phase 1 of clinical trial. There is no treatment related events, dose limiting toxicities were observed at any of the dose levels. The recommended phase 2 dose (RP2D) ultimately selected was dose level 3, which was olaparib 200 mg orally twice daily and temozolomide 75 mg/mg daily.


From the total of 48 patients under the observation and analysis, 20 (41.7%) achieved a response, all of which were partial responses. Among the 39 patients who received the RP2D, the overall response rate was 41.0%, median progression-free survival was 4.2 months (95% CI, 2.5-5.7), and median overall survival was 6.7 months (95% CI, 4.6-12.6).


According to the lead study author Anna Farago, this combination showed significant clinical activity in patients with relapsed small cell lung cancer, and warrants investigation in a randomized study comparing olaparib plus temozolomide with the standard-of-care option.

Need custom market research solution? We can help you with that too.